ME03069B - Antigen vezujući proteini za onkostatin m (osm) - Google Patents

Antigen vezujući proteini za onkostatin m (osm)

Info

Publication number: ME03069B
Authority: ME; Montenegro
Prior art keywords: oncostatin; osm; antigen binding; binding proteins; proteins
Prior art date: 2010-11-23

Application number

MEP-2018-182A

Other languages

German (de)

English (en)

French (fr)

Inventor

Gary Peter Bembridge

Chun-Wa Chung

Maria Feeney

Susannah Karen Ford

Ian Kirby

Ruth Mcadam

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-23

Filing date

2011-11-21

Publication date

2019-01-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45001764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03069(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-11-21 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2019-01-20 Publication of ME03069B publication Critical patent/ME03069B/me

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Investigating Or Analysing Biological Materials (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Measuring Volume Flow (AREA)

MEP-2018-182A 2010-11-23 2011-11-21 Antigen vezujući proteini za onkostatin m (osm) ME03069B (me)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US41649510P	2010-11-23	2010-11-23
EP11785424.0A EP2643352B1 (en)	2010-11-23	2011-11-21	Antigen binding proteins to oncostatin m (osm)
PCT/EP2011/070604 WO2012069433A2 (en)	2010-11-23	2011-11-21	Antigen binding proteins

Publications (1)

Publication Number	Publication Date
ME03069B true ME03069B (me)	2019-01-20

Family

ID=45001764

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2018-182A ME03069B (me)	2010-11-23	2011-11-21	Antigen vezujući proteini za onkostatin m (osm)

Country Status (40)

Country	Link
US (4)	US8916695B2 (me)
EP (3)	EP3369744A1 (me)
JP (2)	JP6351973B2 (me)
KR (2)	KR101947356B1 (me)
CN (1)	CN103328508B (me)
AR (1)	AR083937A1 (me)
AU (1)	AU2011333878B2 (me)
BR (1)	BR112013012627A2 (me)
CA (1)	CA2818534A1 (me)
CL (1)	CL2013001466A1 (me)
CO (1)	CO6801627A2 (me)
CY (1)	CY1120448T1 (me)
DK (1)	DK2643352T3 (me)
DO (1)	DOP2013000113A (me)
EA (1)	EA027256B1 (me)
ES (1)	ES2681949T3 (me)
HR (1)	HRP20181092T1 (me)
HU (1)	HUE039412T2 (me)
IL (1)	IL226157B (me)
JO (1)	JO3455B1 (me)
LT (1)	LT2643352T (me)
MA (1)	MA34742B1 (me)
ME (1)	ME03069B (me)
MX (1)	MX351887B (me)
MY (1)	MY170404A (me)
NZ (1)	NZ610464A (me)
PE (1)	PE20140519A1 (me)
PH (1)	PH12013501036B1 (me)
PL (1)	PL2643352T3 (me)
PT (1)	PT2643352T (me)
RS (1)	RS57502B1 (me)
SG (2)	SG10201500388PA (me)
SI (1)	SI2643352T1 (me)
SM (1)	SMT201800397T1 (me)
TR (1)	TR201810773T4 (me)
TW (1)	TWI504609B (me)
UA (1)	UA111954C2 (me)
UY (1)	UY33743A (me)
WO (1)	WO2012069433A2 (me)
ZA (1)	ZA201303541B (me)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH12013500703A1 (en)	2010-10-13	2013-05-20	Janssen Biotech Inc	Human oncostatin m antibodies and methods of use
AR083937A1 (es)	2010-11-23	2013-04-10	Glaxo Group Ltd	Proteinas de union a antigenos
US9550828B2 (en)	2013-09-05	2017-01-24	Boise State University	Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
US20170327573A1 (en)	2014-09-24	2017-11-16	Universitá Degli Studi Di Padova	Composition to induce bone marrow stem cell mobilization
KR20170132143A (ko) *	2015-01-29	2017-12-01	옥스포드 유니버시티 이노베이션 리미티드	바이오마커
GB201614627D0 (en) *	2016-08-30	2016-10-12	Glaxosmithkline Ip Dev Ltd	Antigen binding proteins
FR3090637A1 (fr) *	2018-12-21	2020-06-26	Universite De Poitiers	Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations.
US11633457B2 (en)	2019-04-11	2023-04-25	Boise State University	Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use
TWI904261B (zh)	2020-10-19	2025-11-11	美商碩騰服務公司	犬及貓抑瘤素Ｍ受體β之抗體及其用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57106673A (en)	1980-12-24	1982-07-02	Chugai Pharmaceut Co Ltd	Dibenzo(b,f)(1,4)oxazepin derivative
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4666884A (en)	1984-04-10	1987-05-19	New England Deaconess Hospital	Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
WO1988007089A1 (en)	1987-03-18	1988-09-22	Medical Research Council	Altered antibodies
US4873316A (en)	1987-06-23	1989-10-10	Biogen, Inc.	Isolation of exogenous recombinant proteins from the milk of transgenic mammals
AU654811B2 (en)	1990-03-20	1994-11-24	Trustees Of Columbia University In The City Of New York, The	Chimeric antibodies with receptor binding ligands in place of their constant region
WO1993022332A2 (en)	1992-04-24	1993-11-11	Board Of Regents, The University Of Texas System	Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5783672A (en) *	1994-05-26	1998-07-21	Immunex Corporation	Receptor for oncostatin M
GB9424449D0 (en)	1994-12-02	1995-01-18	Wellcome Found	Antibodies
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US5747035A (en)	1995-04-14	1998-05-05	Genentech, Inc.	Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
WO1997043316A1 (en)	1996-05-10	1997-11-20	Beth Israel Deaconess Medical Center, Inc.	Physiologically active molecules with extended half-lives and methods of using same
DE19742706B4 (de)	1997-09-26	2013-07-25	Pieris Proteolab Ag	Lipocalinmuteine
US5958442A (en) *	1997-10-24	1999-09-28	Bristol-Myers Squibb Company	Oncostatin M for treating inflammation
CZ20003099A3 (cs)	1998-02-25	2002-04-17	Lexigen Pharmaceuticals Corporation	Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek
GB9806530D0 (en) *	1998-03-26	1998-05-27	Glaxo Group Ltd	Inflammatory mediator
GB9809839D0 (en)	1998-05-09	1998-07-08	Glaxo Group Ltd	Antibody
EP1105427A2 (en)	1998-08-17	2001-06-13	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
IL127127A0 (en)	1998-11-18	1999-09-22	Peptor Ltd	Small functional units of antibody heavy chain variable regions
US6818418B1 (en)	1998-12-10	2004-11-16	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en)	1998-12-10	2006-10-03	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
HU230769B1 (hu)	1999-01-15	2018-03-28	Genentech Inc.	Módosított effektor-funkciójú polipeptid-változatok
EP1176195B1 (en)	1999-04-09	2013-05-22	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
CA2388245C (en)	1999-10-19	2012-01-10	Kyowa Kirin Co., Ltd.	The use of serum-free adapted rat cells for producing heterologous polypeptides
EP1148065B1 (en) *	2000-04-21	2008-01-02	CONARIS research institute AG	Fusion proteins comprising two soluble gp130 molecules
DE60140474D1 (de)	2000-09-08	2009-12-24	Univ Zuerich	Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6374470B1 (en)	2000-10-06	2002-04-23	Milliken & Company	Face plate for spun-like textured yarn
PT1355919E (pt)	2000-12-12	2011-03-02	Medimmune Llc	Moléculas com semivida longa, composições que as contêm e suas utilizações
MXPA05000511A (es) *	2001-07-12	2005-09-30	Jefferson Foote	Anticuepros super humanizados.
EP2180044A1 (en)	2001-08-03	2010-04-28	GlycArt Biotechnology AG	Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
CA2763913C (en)	2001-08-10	2014-10-28	Aberdeen University	Antigen binding domains
US7993650B2 (en)	2003-07-04	2011-08-09	Affibody Ab	Polypeptides having binding affinity for HER2
WO2005019255A1 (en)	2003-08-25	2005-03-03	Pieris Proteolab Ag	Muteins of tear lipocalin
PE20050925A1 (es) *	2003-11-10	2005-11-29	Schering Corp	Anticuerpo recombinante humanizado anti-interleuquina 10
CN1946417A (zh)	2003-12-05	2007-04-11	阿德内克休斯治疗公司	2型血管内皮生长因子受体的抑制剂
HRP20110657T1 (hr) *	2004-03-30	2011-10-31	Glaxo Group Limited	Imunoglobulin koji se veže na osm
GB0407197D0 (en) *	2004-03-30	2004-05-05	Glaxo Group Ltd	Immunoglobulins
JP2008512353A (ja)	2004-07-21	2008-04-24	グライコフィ，インコーポレイテッド	主にＧｌｃＮＡｃ２Ｍａｎ３ＧｌｃＮＡｃ２グリコフォームを含むイムノグロブリン
JP4997108B2 (ja)	2005-07-22	2012-08-08	協和発酵キリン株式会社	遺伝子組換え抗体組成物
US7923538B2 (en)	2005-07-22	2011-04-12	Kyowa Hakko Kirin Co., Ltd	Recombinant antibody composition
CA2652733C (en) *	2006-05-25	2016-06-21	Glaxo Group Limited	Modified humanised anti-interleukin-18 antibodies
EP1958957A1 (en)	2007-02-16	2008-08-20	NascaCell Technologies AG	Polypeptide comprising a knottin protein moiety
WO2010056893A1 (en) *	2008-11-13	2010-05-20	Imclone Llc	Humanization and affinity-optimization of antibodies
PH12013500703A1 (en) *	2010-10-13	2013-05-20	Janssen Biotech Inc	Human oncostatin m antibodies and methods of use
AR083937A1 (es)	2010-11-23	2013-04-10	Glaxo Group Ltd	Proteinas de union a antigenos

2011
- 2011-11-21 AR ARP110104328A patent/AR083937A1/es unknown
- 2011-11-21 KR KR1020187027871A patent/KR101947356B1/ko not_active Expired - Fee Related
- 2011-11-21 PE PE2013001238A patent/PE20140519A1/es active IP Right Grant
- 2011-11-21 ES ES11785424.0T patent/ES2681949T3/es active Active
- 2011-11-21 BR BR112013012627A patent/BR112013012627A2/pt not_active Application Discontinuation
- 2011-11-21 SG SG10201500388PA patent/SG10201500388PA/en unknown
- 2011-11-21 DK DK11785424.0T patent/DK2643352T3/en active
- 2011-11-21 NZ NZ610464A patent/NZ610464A/en not_active IP Right Cessation
- 2011-11-21 TW TW100142577A patent/TWI504609B/zh not_active IP Right Cessation
- 2011-11-21 JP JP2013539295A patent/JP6351973B2/ja not_active Expired - Fee Related
- 2011-11-21 US US13/989,191 patent/US8916695B2/en active Active
- 2011-11-21 ME MEP-2018-182A patent/ME03069B/me unknown
- 2011-11-21 JO JOP/2011/0353A patent/JO3455B1/ar active
- 2011-11-21 PH PH1/2013/501036A patent/PH12013501036B1/en unknown
- 2011-11-21 SI SI201131537T patent/SI2643352T1/sl unknown
- 2011-11-21 AU AU2011333878A patent/AU2011333878B2/en not_active Ceased
- 2011-11-21 CA CA2818534A patent/CA2818534A1/en not_active Abandoned
- 2011-11-21 KR KR1020137016213A patent/KR20130119948A/ko not_active Ceased
- 2011-11-21 UY UY0001033743A patent/UY33743A/es not_active Application Discontinuation
- 2011-11-21 HU HUE11785424A patent/HUE039412T2/hu unknown
- 2011-11-21 EP EP18163940.2A patent/EP3369744A1/en not_active Withdrawn
- 2011-11-21 EP EP11785424.0A patent/EP2643352B1/en active Active
- 2011-11-21 LT LTEP11785424.0T patent/LT2643352T/lt unknown
- 2011-11-21 HR HRP20181092TT patent/HRP20181092T1/hr unknown
- 2011-11-21 CN CN201180065512.0A patent/CN103328508B/zh not_active Expired - Fee Related
- 2011-11-21 SM SM20180397T patent/SMT201800397T1/it unknown
- 2011-11-21 EA EA201390537A patent/EA027256B1/ru not_active IP Right Cessation
- 2011-11-21 PT PT117854240T patent/PT2643352T/pt unknown
- 2011-11-21 UA UAA201305873A patent/UA111954C2/uk unknown
- 2011-11-21 EP EP17166131.7A patent/EP3211009A1/en not_active Withdrawn
- 2011-11-21 SG SG2013035951A patent/SG190232A1/en unknown
- 2011-11-21 MY MYPI2013700832A patent/MY170404A/en unknown
- 2011-11-21 PL PL11785424T patent/PL2643352T3/pl unknown
- 2011-11-21 WO PCT/EP2011/070604 patent/WO2012069433A2/en not_active Ceased
- 2011-11-21 MX MX2013005843A patent/MX351887B/es active IP Right Grant
- 2011-11-21 TR TR2018/10773T patent/TR201810773T4/tr unknown
- 2011-11-21 RS RS20180819A patent/RS57502B1/sr unknown
2013
- 2013-05-05 IL IL226157A patent/IL226157B/en active IP Right Grant
- 2013-05-15 ZA ZA2013/03541A patent/ZA201303541B/en unknown
- 2013-05-17 CO CO13122422A patent/CO6801627A2/es unknown
- 2013-05-21 DO DO2013000113A patent/DOP2013000113A/es unknown
- 2013-05-23 CL CL2013001466A patent/CL2013001466A1/es unknown
- 2013-06-19 MA MA36018A patent/MA34742B1/fr unknown
2014
- 2014-11-13 US US14/540,247 patent/US9605063B2/en not_active Expired - Fee Related
2016
- 2016-11-11 JP JP2016220093A patent/JP2017078072A/ja active Pending
2017
- 2017-02-09 US US15/428,528 patent/US10808029B2/en not_active Expired - Fee Related
2018
- 2018-07-24 CY CY20181100770T patent/CY1120448T1/el unknown
2020
- 2020-07-09 US US16/924,628 patent/US20210017270A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EA201390537A1 (ru)	2014-01-30
MY170404A (en)	2019-07-27
EP3369744A1 (en)	2018-09-05
US10808029B2 (en)	2020-10-20
KR101947356B1 (ko)	2019-02-12
MX351887B (es)	2017-11-01
PE20140519A1 (es)	2014-04-30
WO2012069433A2 (en)	2012-05-31
UY33743A (es)	2012-06-29
EP2643352B1 (en)	2018-05-02
KR20130119948A (ko)	2013-11-01
EP3211009A1 (en)	2017-08-30
US20210017270A1 (en)	2021-01-21
PH12013501036B1 (en)	2019-05-10
CA2818534A1 (en)	2012-05-31
LT2643352T (lt)	2018-08-10
CO6801627A2 (es)	2013-11-29
TR201810773T4 (tr)	2018-08-27
UA111954C2 (uk)	2016-07-11
TWI504609B (zh)	2015-10-21
JP2014507373A (ja)	2014-03-27
EA027256B1 (ru)	2017-07-31
BR112013012627A2 (pt)	2016-10-04
ES2681949T3 (es)	2018-09-17
HRP20181092T1 (hr)	2018-09-21
US20150064201A1 (en)	2015-03-05
IL226157A0 (en)	2013-06-27
HUE039412T2 (hu)	2018-12-28
US20130251724A1 (en)	2013-09-26
US20170152312A1 (en)	2017-06-01
MA34742B1 (fr)	2013-12-03
NZ610464A (en)	2015-02-27
US8916695B2 (en)	2014-12-23
PT2643352T (pt)	2018-08-01
SMT201800397T1 (it)	2018-09-13
SG10201500388PA (en)	2015-03-30
MX2013005843A (es)	2013-07-05
DK2643352T3 (en)	2018-07-30
SG190232A1 (en)	2013-06-28
CL2013001466A1 (es)	2014-06-27
CN103328508B (zh)	2015-12-16
RS57502B1 (sr)	2018-10-31
KR20180110199A (ko)	2018-10-08
TW201235358A (en)	2012-09-01
JO3455B1 (ar)	2020-07-05
PH12013501036A1 (en)	2013-07-15
EP2643352A2 (en)	2013-10-02
WO2012069433A3 (en)	2012-08-09
PL2643352T3 (pl)	2018-10-31
ZA201303541B (en)	2014-11-26
US9605063B2 (en)	2017-03-28
AU2011333878B2 (en)	2016-01-14
DOP2013000113A (es)	2013-12-15
CY1120448T1 (el)	2019-07-10
SI2643352T1 (sl)	2018-12-31
JP6351973B2 (ja)	2018-07-04
AR083937A1 (es)	2013-04-10
CN103328508A (zh)	2013-09-25
AU2011333878A1 (en)	2013-05-09
IL226157B (en)	2020-10-29
JP2017078072A (ja)	2017-04-27

Publication	Publication Date	Title
CY2019040I2 (el)	2020-05-29	Aνti-il-23 αντισωματα
CO7020862A2 (es)	2014-08-11	Proteinas de unión al antígeno cd27l
IL287824A (en)	2022-01-01	Oncostatin m receptor antigen-binding proteins
SG10201401681PA (en)	2014-07-30	Novel antigen binding proteins
DK2606061T3 (da)	2017-11-06	Bindingsproteiner til hepcidin
BR112013030352A2 (pt)	2017-08-01	proteínas de ligação do receptor fc
DK3741883T3 (da)	2023-02-20	Antistofbiblioteker
ME03069B (me)	2019-01-20	Antigen vezujući proteini za onkostatin m (osm)
EP2681239B8 (en)	2015-09-09	Antigen binding proteins
DK2850103T3 (da)	2020-09-07	ST2-antigenbindende proteiner
CO6791565A2 (es)	2013-11-14	Anticuerpos anti-notch1
DK2531526T3 (da)	2017-11-13	Fremgangsmåde til opnåelse af antistoffer
DK2721152T3 (da)	2019-07-01	Dimere bindingsproteiner baseret på modificerede ubiquitiner
ZA201305865B (en)	2023-08-30	Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
FI20106367A0 (fi)	2010-12-22	Menetelmä proteiinisynteesin tehostamiseksi
DOP2011000313A (es)	2011-12-31	Anticuerpos especificos para caderin-17